KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bionano Genomics (BNGO) Shares Outstanding (Weighted Average) (2017 - 2025)

Bionano Genomics' Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $3.8 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 234.12% year-over-year to $3.8 million; the TTM value through Sep 2025 reached $3.8 million, up 234.12%, while the annual FY2024 figure was $1.3 million, 123.37% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $3.8 million at Bionano Genomics, up from $3.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $284.6 million in Q1 2022 and bottomed at $569000.0 in Q4 2023.
  • The 5-year median for Shares Outstanding (Weighted Average) is $28.7 million (2022), against an average of $82.6 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) surged 642.05% in 2021 before it crashed 98.03% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $276.8 million in 2021, then crashed by 89.55% to $28.9 million in 2022, then plummeted by 98.03% to $569000.0 in 2023, then skyrocketed by 123.37% to $1.3 million in 2024, then skyrocketed by 201.26% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Shares Outstanding (Weighted Average) are $3.8 million (Q3 2025), $3.1 million (Q2 2025), and $2.7 million (Q1 2025).